Share on StockTwits

Ophthotech Corp (NASDAQ:OPHT) Director Nicholas Galakatos unloaded 144,976 shares of Ophthotech Corp stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $44.17, for a total value of $6,403,589.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ophthotech Corp (NASDAQ:OPHT) traded down 0.23% on Monday, hitting $43.90. 189,583 shares of the company’s stock traded hands. Ophthotech Corp has a one year low of $22.61 and a one year high of $47.99. The stock has a 50-day moving average of $37.30 and a 200-day moving average of $33.95. The company’s market cap is $1.464 billion. Ophthotech Corp also was the recipient of a large decline in short interest in May. As of May 30th, there was short interest totalling 1,679,936 shares, a decline of 27.8% from the May 15th total of 2,327,392 shares. Approximately 9.8% of the company’s stock are short sold. Based on an average trading volume of 815,564 shares, the short-interest ratio is currently 2.1 days.

Ophthotech Corp (NASDAQ:OPHT) last announced its earnings results on Tuesday, May 13th. The company reported ($0.64) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.67) by $0.03. On average, analysts predict that Ophthotech Corp will post $-2.11 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on OPHT shares. Analysts at Morgan Stanley raised their price target on shares of Ophthotech Corp from $79.00 to $99.00 in a research note on Tuesday, May 20th. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Ophthotech Corp from $40.00 to $51.00 in a research note on Tuesday, May 20th. They now have an “overweight” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Ophthotech Corp from $55.00 to $58.00 in a research note on Tuesday, May 20th. They now have a “buy” rating on the stock.

Ophthotech Corporation is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.